Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
View Patent ↗The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
1. A method of producing a monoclonal antibody comprising culturing a hybridoma that produces a monoclonal antibody that binds to an isolated polypeptide consisting of amino acid residues 1 to 229 of SEQ ID NO: 2, and purifying the monoclonal antibody from the culture supernatant.
2. The method of claim 1 , which further comprises immunizing an animal with an isolated polypeptide consisting of amino acid residues 1 to 229 of SEQ ID NO: 2, and fusing spleen cells from the immunized animal with myeloma cells to produce hybridoma cells which produce antibodies.
3. A method of producing a monoclonal antibody comprising culturing a hybridoma that produces a monoclonal antibody that binds to an isolated polypeptide consisting of amino acid residues 27 to position 427 of SEQ ID NO: 2, and purifying the monoclonal antibody from the culture supernatant.
4. The method of claim 3 , which further comprises immunizing an animal with an isolated polypeptide consisting of amino acid residues 27 to position 427 of SEQ ID NO: 2, and fusing spleen cells from the immunized animal with myeloma cells to produce hybridoma cells which produce antibodies.
5. A method of producing a hybridoma, the method comprising contacting stimulated B-lymphocytes in vitro with an isolated polypeptide consisting of amino acid residues 1 to 229 of SEQ ID NO: 2, fusing the resultant B-lymphocytes with B-lymphocytes immortalized with Epstein Barr virus, and isolating hybridoma cells which produce antibodies.
6. The method of claim 5 , further comprising culturing the hybridoma cells and purifying a monoclonal antibody from the culture supernatant.
7. A method of producing hybridoma, the method comprising contacting stimulated B-lymphocytes in vitro with an isolated polypeptide consisting of amino acid residues 27 to position 427 of SEQ ID NO: 2, fusing the resultant B-lymphocytes with B-lymphocytes immortalized with Epstein Barr virus, and isolating hybridoma cells which produce antibodies.
8. The method of claim 7 , further comprising culturing the hybridoma cells and purifying a monoclonal antibody from the culture supernatant.
9. The method of claim 1 , wherein said monoclonal antibody is directed against the human interferon type 1 receptor (IFN-R) and has neutralizing capacity in vitro against the human type I-IFN.
10. The method of claim 3 , wherein said monoclonal antibody is directed against the human interferon type 1 receptor (IFN-R) and has neutralizing capacity in vitro against the human type I-IFN.
11. The method of claim 6 , wherein said monoclonal antibody is directed against the human interferon type 1 receptor (IFN-R) and has neutralizing capacity in vitro against the human type I-IFN.
12. The method of claim 8 , wherein said monoclonal antibody is directed against the human interferon type 1 receptor (IFN-R) and has neutralizing capacity in vitro against the human type I-IFN.
13. The method of claim 1 , wherein said monoclonal antibody is capable of inhibiting the binding of a human type I-IFN to the human interferon type 1 receptor (IFN-R).
14. The method of claim 3 , wherein said monoclonal antibody is capable of inhibiting the binding of a human type I-IFN to the human interferon type 1 receptor (IFN-R).
15. The method of claim 6 , wherein said monoclonal antibody is capable of inhibiting the binding of a human type I-IFN to the human interferon type 1 receptor (IFN-R).
16. The method of claim 8 , wherein said monoclonal antibody is capable of inhibiting the binding of a human type I-IFN to the human interferon type 1 receptor (IFN-R).